Back to search

Article

Allelic Variation in<i>HLA-DRB1</i>is Associated with Development of Anti-Drug Antibodies in Cancer Patients Treated with Atezolizumab that are Neutralizing<i>in Vitro</i>

2021-05-03

Abstract excerpt

The treatment of diseases with biologic agents can result in the formation of anti-drug antibodies (ADA). The occurrence of ADA were reported for atezolizumab, an anti-PD-L1 monoclonal antibody widely used as immunotherapeutic treatment in cancer patients. Although drivers for ADA formation are unknown, a role for antigen presentation is likely, and variation in human leukocyte antigen (HLA) genes has been shown t...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
733713a6-9fc2-52b5-92dc-379bea28dd65
DOI
10.1101/2021.04.29.21256008
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Allelic Variation in<i>HLA-DRB1</i>is Associated with Development of Anti-Drug Antibodies in Cancer Patients Treated with Atezolizumab that are Neutralizing<i>in Vitro</i>DOI 10.1101/2021.04.29.21256008
Allelic variation in HLA-DRB1 is associated with development of antidrug antibodies in cancer patients treated with atezolizumab that are neutralizing in vitro.Semantic proximity
HLA Class II Alleles are associated with Anti-Drug Antibodies in Ulcerative Colitis Patients Treated with EtrolizumabSemantic proximity
HLA Class II Alleles Are Associated With Anti-Drug Antibodies in Ulcerative Colitis Patients Treated With Etrolizumab.Semantic proximity
Identification of HLA-DRB1 association to adalimumab immunogenicity.Semantic proximity
Next generation of anti-PD-L1 Atezolizumab with better anti-tumor efficacy <i>in vivo</i>Semantic proximity
Immunogenicity of Monoclonal Antibodies and the Potential Use of HLA Haplotypes to Predict Vulnerable PatientsSemantic proximity
Immunogenicity of Therapeutic Antibodies: Mechanisms, Prediction, and Mitigation Strategies in the Era of Personalized BiologicsSemantic proximity
HLA Class II Alleles DRB1*11:01 and DQB1*03:01 Unmask Immunogenetic Susceptibility to Anti-Nivolumab Antibodies in Combination with Ipilimumab.Semantic proximity
HLA-DQA1*05 is associated with the development of antibodies to anti-TNF therapySemantic proximity
16th IHIW: a website for antibody-defined HLA epitope Registry.Semantic proximity
Association between germ-line HLA and immune-related adverse eventsSemantic proximity
Informatics investigations into anti-thyroid drug induced agranulocytosis associated with multiple HLA-B alleles.Semantic proximity
Select a neighboring publication to make it the new centre.